{"anticipatedPostingDate":"2030-11","denomUnitsSelected":"Participants","description":"PFS2 defined as time from randomization to disease progression (investigator-assessed response) after initiation of new anti-myeloma therapy or death from any cause, whichever is earlier. If disease progression after new antimyeloma therapy cannot be measured, a PFS event is defined as the date of discontinuation of new anti-myeloma therapy, or death from any cause, whichever is earlier.","reportingStatus":"NOT_POSTED","timeFrame":"Up to approximately 407 weeks","title":"Progression-free Survival on Subsequent Line of Therapy (PFS2)","type":"SECONDARY"}